Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial

BACKGROUND: Booster vaccination is an efficient way to address the waning protection of vaccines and immune escape of SARS-CoV-2 variants. We aimed to assess the safety and immunogenicity of SCTV01C, a novel bivalent protein vaccine as a booster for people who previously received two doses of mRNA v...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannawi, Suad, Saifeldin, Linda, Abuquta, Alaa, Alamadi, Ahmad, Mahmoud, Sally A., Hassan, Aala, Liu, Dongfang, Yan, Lixin, Xie, Liangzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720098/
https://www.ncbi.nlm.nih.gov/pubmed/36470077
http://dx.doi.org/10.1016/j.ebiom.2022.104386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720098/
https://www.ncbi.nlm.nih.gov/pubmed/36470077
http://dx.doi.org/10.1016/j.ebiom.2022.104386

Ejemplares similares